News for Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development o

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy.  In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc.

On March 14, Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the markets react to crises and what approach investors should take...

Revenue (FY 2024): $152.3 million, a decrease from $166.8 million in 2023.Revenue (Q4 2024): $22.8 million, down from $30.9 million in Q4 2023.Net Loss (FY 202

Mar 06, 2025 / 09:30PM GMTOperator Thank you for holding, ladies and gentlemen. We thank you for your patience and ask that you please continue to hold. Good da

Arcturus Therapeutics Holdings Inc (ARCT) is set to release its Q4 2024 earnings on Mar 6, 2025. The consensus estimate for Q4 2024 revenue is $44.65 million, a

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

PR NewswireWALTHAM, Mass. and SAN DIEGO, Feb. 14, 2025 - KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immuno

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Arcturus Therapeutics stock hits 52-week low at $14.82

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Cathie Wood's ARK buys ARCT, TXG, and sells VEEV, EXAS stock

Cathie Wood's ARK trades Trade Desk and CRISPR stock, sells Unity

With over 80 key companies active in the RNA therapies space, the market is projected to grow due to advancements in mRNA, siRNA, and antisense...

Arcturus shares gain as William Blair affirms Outperform rating